Pages that link to "Q34664835"
Jump to navigation
Jump to search
The following pages link to The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects. (Q34664835):
Displaying 50 items.
- Pharmacological and Safety Profile of Dexlansoprazole: A New Proton Pump Inhibitor - Implications for Treatment of Gastroesophageal Reflux Disease in the Asia Pacific Region (Q26765113) (← links)
- NSAIDs and Cardiovascular Diseases: Role of Reactive Oxygen Species (Q26784322) (← links)
- Data-driven identification of structural alerts for mitigating the risk of drug-induced human liver injuries (Q27902347) (← links)
- Using expression and genotype to predict drug response in yeast (Q28476059) (← links)
- Inhibitors of the glyoxylate cycle enzyme ICL1 in Candida albicans for potential use as antifungal agents (Q28538283) (← links)
- A novel CMKLR1 small molecule antagonist suppresses CNS autoimmune inflammatory disease (Q28542368) (← links)
- Auto-Induction Effect of Chloroxoquinoline on the Cytochrome P450 Enzymes of Rats Associated with CYP 3A and 1A (Q28548385) (← links)
- Advances in structure elucidation of small molecules using mass spectrometry (Q28743720) (← links)
- Hepatitis C and kidney disease: A narrative review (Q30238652) (← links)
- A quick review of carbamazepine pharmacokinetics in epilepsy from 1953 to 2012 (Q30486339) (← links)
- Frequency and clinical relevance of potential cytochrome P450 drug interactions in a psychiatric patient population - an analysis based on German insurance claims data. (Q31127895) (← links)
- Cytochrome P-450 1B1 Leu432Val Polymorphism Does Not Show Association With Breast Cancer in Northern Iranian Women With a History of Infertility. (Q33565758) (← links)
- Pharmacogenetic testing revisited: 5' nuclease real-time polymerase chain reaction test panels for genotyping CYP2D6 and CYP2C19. (Q33597438) (← links)
- The Impact of CYP2D6 Genotyping on Tamoxifen Treatment (Q33664433) (← links)
- Integrated safety analysis of rolapitant with coadministered drugs from phase II/III trials: an assessment of CYP2D6 or BCRP inhibition by rolapitant (Q33749075) (← links)
- Analysis of CYP2C9*2, CYP2C19*2, and CYP2D6*4 polymorphisms in patients with type 2 diabetes mellitus (Q33847923) (← links)
- Factors affecting the long-term response to tacrolimus in renal transplant patients: pharmacokinetic and pharmacogenetic approach (Q33849108) (← links)
- Analysis of single-nucleotide polymorphisms (SNPs) in human CYP3A4 and CYP3A5 genes: potential implications for the metabolism of HIV drugs (Q33850686) (← links)
- Inhibition of Human Cytochrome P450 Enzymes by Allergen Removed Rhus verniciflua Stoke Standardized Extract and Constituents (Q33908260) (← links)
- Patient attitudinal and behavioral factors associated with warfarin non-adherence at outpatient anticoagulation clinics. (Q34056113) (← links)
- Bioreactor technologies to support liver function in vitro. (Q34087508) (← links)
- Exploration of 3-Aminoazetidines as Triple Reuptake Inhibitors by Bioisosteric Modification of 3-α-Oxyazetidine (Q34162662) (← links)
- Modeling chemical interaction profiles: I. Spectral data-activity relationship and structure-activity relationship models for inhibitors and non-inhibitors of cytochrome P450 CYP3A4 and CYP2D6 isozymes (Q34197418) (← links)
- Modeling chemical interaction profiles: II. Molecular docking, spectral data-activity relationship, and structure-activity relationship models for potent and weak inhibitors of cytochrome P450 CYP3A4 isozyme (Q34197425) (← links)
- Pharmacokinetics of artemether and dihydroartemisinin in healthy Pakistani male volunteers treated with artemether-lumefantrine (Q34221884) (← links)
- Cytochrome P450 single nucleotide polymorphisms in an indigenous Tanzanian population: a concern about the metabolism of artemisinin-based combinations (Q34491448) (← links)
- Cytochrome P450 induction properties of food and herbal-derived compounds using a novel multiplex RT-qPCR in vitro assay, a drug-food interaction prediction tool (Q34542725) (← links)
- Glycyrrhetinic acid and E.resveratroloside act as potential plant derived compounds against dopamine receptor D3 for Parkinson's disease: a pharmacoinformatics study (Q34770959) (← links)
- CYP1B1 enhances the resistance of epithelial ovarian cancer cells to paclitaxel in vivo and in vitro (Q34936845) (← links)
- Addressing phenoconversion: the Achilles' heel of personalized medicine (Q35023701) (← links)
- Active-site hydration and water diffusion in cytochrome P450cam: a highly dynamic process. (Q35224013) (← links)
- Pharmacoinformatics approach for investigation of alternative potential hepatitis C virus nonstructural protein 5B inhibitors. (Q35248674) (← links)
- Pharmacokinetics and pharmacodynamics following maintenance doses of prasugrel and clopidogrel in Chinese carriers of CYP2C19 variants (Q35640465) (← links)
- Adaptive evolution and elucidating the potential inhibitor against schizophrenia to target DAOA (G72) isoforms (Q35841574) (← links)
- Potential cytochrome P-450 drug-drug interactions in adults with metastatic solid tumors and effect on eligibility for Phase I clinical trials (Q35878347) (← links)
- Antioxidant, Hepatoprotective Potential and Chemical Profiling of Propolis Ethanolic Extract from Kashmir Himalaya Region Using UHPLC-DAD-QToF-MS. (Q36204077) (← links)
- Clinical pharmacology in sleep medicine (Q36417984) (← links)
- Advancing personalized health care through health information technology: an update from the American Health Information Community's Personalized Health Care Workgroup (Q36741461) (← links)
- Pharmacoinformatic and molecular docking studies reveal potential novel antidepressants against neurodegenerative disorders by targeting HSPB8. (Q36900533) (← links)
- Preliminarily Analysis of Carbamazepine (CBZ) C0 in Patients Visited Isfahan Epileptic Clinics (Q36917811) (← links)
- Molecular and macromolecular alterations of recombinant adenoviral vectors do not resolve changes in hepatic drug metabolism during infection (Q36932523) (← links)
- Studying copy number variations using a nanofluidic platform (Q36935421) (← links)
- Molecular mechanisms underlying chemical liver injury (Q36991523) (← links)
- Effect of cranberry dietary supplements with different brands on human CYP3A4 enzyme (Q37054184) (← links)
- Nuclear Receptors in Drug Metabolism, Drug Response and Drug Interactions (Q37130938) (← links)
- Past 12-month and lifetime comorbidity and poly-drug use of ecstasy users among young adults in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions (Q37166739) (← links)
- Use of drugs that act on the cytochrome P450 system in the elderly (Q37222734) (← links)
- Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease (Q37259929) (← links)
- Pharmacogenomics in clinical practice and drug development (Q37284234) (← links)
- Physical Studies of P450-P450 Interactions: Predicting Quaternary Structures of P450 Complexes in Membranes from Their X-ray Crystal Structures (Q37611698) (← links)